These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 34762160)
41. Drug Repurposing in Pediatric Brain Tumors: Posterior Fossa Ependymoma and Diffuse Midline Glioma under the Looking Glass. Servidei T; Sgambato A; Lucchetti D; Navarra P; Ruggiero A Front Biosci (Landmark Ed); 2023 Apr; 28(4):77. PubMed ID: 37114548 [TBL] [Abstract][Full Text] [Related]
42. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis. Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636 [TBL] [Abstract][Full Text] [Related]
43. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study. Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777 [TBL] [Abstract][Full Text] [Related]
44. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods. de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940 [TBL] [Abstract][Full Text] [Related]
46. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification. Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871 [TBL] [Abstract][Full Text] [Related]
47. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond. Kresbach C; Neyazi S; Schüller U Brain Pathol; 2022 Jul; 32(4):e13068. PubMed ID: 35307892 [TBL] [Abstract][Full Text] [Related]
48. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation. Neyazi S; Yamazawa E; Hack K; Tanaka S; Nagae G; Kresbach C; Umeda T; Eckhardt A; Tatsuno K; Pohl L; Hana T; Bockmayr M; Kim P; Dorostkar MM; Takami T; Obrecht D; Takai K; Suwala AK; Komori T; Godbole S; Wefers AK; Otani R; Neumann JE; Higuchi F; Schweizer L; Nakanishi Y; Monoranu CM; Takami H; Engertsberger L; Yamada K; Ruf V; Nomura M; Mohme T; Mukasa A; Herms J; Takayanagi S; Mynarek M; Matsuura R; Lamszus K; Ishii K; Kluwe L; Imai H; von Deimling A; Koike T; Benesch M; Kushihara Y; Snuderl M; Nambu S; Frank S; Omura T; Hagel C; Kugasawa K; Mautner VF; Ichimura K; Rutkowski S; Aburatani H; Saito N; Schüller U Acta Neuropathol; 2024 Jan; 147(1):22. PubMed ID: 38265489 [TBL] [Abstract][Full Text] [Related]
49. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas. Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522 [TBL] [Abstract][Full Text] [Related]
50. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups. Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133 [TBL] [Abstract][Full Text] [Related]
51. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586 [TBL] [Abstract][Full Text] [Related]
52. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study. Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248 [TBL] [Abstract][Full Text] [Related]
53. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Hoffman LM; Donson AM; Nakachi I; Griesinger AM; Birks DK; Amani V; Hemenway MS; Liu AK; Wang M; Hankinson TC; Handler MH; Foreman NK Acta Neuropathol; 2014 May; 127(5):731-45. PubMed ID: 24240813 [TBL] [Abstract][Full Text] [Related]
54. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B. Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725 [TBL] [Abstract][Full Text] [Related]
55. Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups. Sabin ND; Hwang SN; Klimo P; Chambwe N; Tatevossian RG; Patni T; Li Y; Boop FA; Anderson E; Gajjar A; Merchant TE; Ellison DW AJNR Am J Neuroradiol; 2021 Dec; 42(12):2245-2250. PubMed ID: 34674998 [TBL] [Abstract][Full Text] [Related]
57. Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. Benesch M; Mynarek M; Witt H; Warmuth-Metz M; Pietsch T; Bison B; Pfister SM; Pajtler KW; Kool M; Schüller U; Pietschmann K; Juhnke BO; Tippelt S; Fleischhack G; Schmid I; Kramm CM; Vorwerk P; Beilken A; Classen CF; Hernáiz Driever P; Kropshofer G; Imschweiler T; Lemmer A; Kortmann RD; Rutkowski S; von Hoff K Oncologist; 2019 Sep; 24(9):e921-e929. PubMed ID: 30850560 [TBL] [Abstract][Full Text] [Related]
58. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel. Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Benevides Silva FA; Dastoli PA; Cavalheiro S; Caminada de Toledo SR J Neurooncol; 2021 Oct; 155(1):13-23. PubMed ID: 34570300 [TBL] [Abstract][Full Text] [Related]
59. CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. Antonelli R; Jiménez C; Riley M; Servidei T; Riccardi R; Soriano A; Roma J; Martínez-Saez E; Martini M; Ruggiero A; Moreno L; Sánchez de Toledo J; Gallego S; Bové J; Hooker JM; Segura MF Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708733 [TBL] [Abstract][Full Text] [Related]
60. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]